New Belviq drug for weight loss

Not so long ago, a new anorectic drug – Belviq has appeared on the shelves of US pharmacies. It was approved by the U.S. FDA in June 2012. The main difference of Belviq from other anorectics, such as Duromine, Adipex P and Phentermine is to use other active substance.

Active substance of Belviq is Lorcaserin hydrochloride.

  • This substance suppresses the person’s appetite and promotes rapid saturation. Herewith, the person feels full of energy and his working capacity increases by several times.

The manufacturer of Belviq is a Swiss pharmaceutical company, Arena Pharmaceuticals GmbH. The drug comes in round blue tablets in the dose of 10 mg.

The tablets debossed with “A” on one side and “10” – on other side. Weight loss experts recommend using Belviq in the combination with physical loads and balanced diet.

Belviq is contraindicated to pregnant women and breastfeeding mothers.

  • A lot of physicians believe weight loss during pregnancy can negatively affect the fetus development and the health state of the pregnant woman.

Although, there are no direct confirmations that active ingredient can pass into breast milk, yet physicians recommend to refrain from Belviq use during nursing.

Belviq is intended for the obesity treatment in adults and adolescents over 18 years old. Elderly people should take Belviq with a special caution. Weak renal function of many elderly patients may require a special monitoring by the doctor and a frequent adjustment of the therapeutic dose of the drug.

Elderly patients with normal renal function do not require the adjustment of Belviq daily dose and the treatment process takes place as usual.

  • The daily dose of Belviq is 20 mg a day (2 tablets). A Belviq tablet is taken in the morning, the other – in the evening.

If you forget to take the therapeutic dose of Belviq, take it as soon as you remember.

  1. If it is almost time for your next scheduled dose, skip the missed dose.
  2. It is not recommended to take extra medicine to make up the missed dose.

During the obesity treatment, avoid increasing the recommended dose. Exactly the increase in the daily dose contributes to the occurrence of insomnia and unwanted side effects.

Clinical trials have shown that the most common side effects of Belviq are:

  • Nausea
  • Fatigue
  • Constipation
  • Headache
  • Dry mouth
  • Dizziness

The patient should know that Belviq is a drug that affects the central nervous system (CNS). Its effect on certain parts of the brain can cause side effects that are more serious. They may include depression, visual hallucinations, euphoria and dissociation of personality.

Contraindications for Belviq use for the obesity treatment may be diseases, such as liver and / or kidney dysfunction, breast cancer, bradycardia, valvulopathy. Hypersensitivity to the Belviq ingredients may also be a contraindication.

To treat obesity efficiently and without any discomfort, the patient should avoid Belviq overdose and stick to the doctor’s advice.


Comments are closed.